Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
JAMA Oncology
|
June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
The Lancet. Oncology
|
October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2024
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitors
A Di Federico, L Hong, A Elkrief, et al.
Cancer Discovery
|
April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Seshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.
JCO Precision Oncology
|
September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors
Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Cell
|
October 18, 2025
CRATER tumor niches facilitate CD8<sup>+</sup> T cell engagement and correspond with immunotherapy success
Aya Ludin, Georgia L Stirtz, Asaf Tal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 14, 2026
TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitors
Alessandro Di Federico, Lingzhi Hong, Arielle Elkrief, et al.
Journal for Immunotherapy of Cancer
|
February 4, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
JAMA Oncology
|
June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
The Lancet. Oncology
|
October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2024
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitors
A Di Federico, L Hong, A Elkrief, et al.
Cancer Discovery
|
April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Seshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.
JCO Precision Oncology
|
September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors
Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Cell
|
October 18, 2025
CRATER tumor niches facilitate CD8<sup>+</sup> T cell engagement and correspond with immunotherapy success
Aya Ludin, Georgia L Stirtz, Asaf Tal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 14, 2026
TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitors
Alessandro Di Federico, Lingzhi Hong, Arielle Elkrief, et al.
Journal for Immunotherapy of Cancer
|
February 4, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.
Page
of 8